GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » 23andMe Holding Co (NAS:ME) » Definitions » Asset Turnover

23andMe Holding Co (23andMe Holding Co) Asset Turnover : 0.06 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is 23andMe Holding Co Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. 23andMe Holding Co's Revenue for the three months ended in Dec. 2023 was $44.7 Mil. 23andMe Holding Co's Total Assets for the quarter that ended in Dec. 2023 was $704.7 Mil. Therefore, 23andMe Holding Co's Asset Turnover for the quarter that ended in Dec. 2023 was 0.06.

Asset Turnover is linked to ROE % through Du Pont Formula. 23andMe Holding Co's annualized ROE % for the quarter that ended in Dec. 2023 was -221.84%. It is also linked to ROA % through Du Pont Formula. 23andMe Holding Co's annualized ROA % for the quarter that ended in Dec. 2023 was -157.78%.


23andMe Holding Co Asset Turnover Historical Data

The historical data trend for 23andMe Holding Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

23andMe Holding Co Asset Turnover Chart

23andMe Holding Co Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Asset Turnover
- 0.54 0.34 0.29

23andMe Holding Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.09 0.07 0.06 0.06

Competitive Comparison of 23andMe Holding Co's Asset Turnover

For the Diagnostics & Research subindustry, 23andMe Holding Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


23andMe Holding Co's Asset Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, 23andMe Holding Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where 23andMe Holding Co's Asset Turnover falls into.



23andMe Holding Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

23andMe Holding Co's Asset Turnover for the fiscal year that ended in Mar. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=299.489/( (1152.068+942.598)/ 2 )
=299.489/1047.333
=0.29

23andMe Holding Co's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=44.747/( (801.23+608.211)/ 2 )
=44.747/704.7205
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


23andMe Holding Co  (NAS:ME) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

23andMe Holding Co's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-1111.904/501.2195
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1111.904 / 178.988)*(178.988 / 704.7205)*(704.7205/ 501.2195)
=Net Margin %*Asset Turnover*Equity Multiplier
=-621.22 %*0.254*1.406
=ROA %*Equity Multiplier
=-157.78 %*1.406
=-221.84 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

23andMe Holding Co's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-1111.904/704.7205
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1111.904 / 178.988)*(178.988 / 704.7205)
=Net Margin %*Asset Turnover
=-621.22 %*0.254
=-157.78 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


23andMe Holding Co Asset Turnover Related Terms

Thank you for viewing the detailed overview of 23andMe Holding Co's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


23andMe Holding Co (23andMe Holding Co) Business Description

Traded in Other Exchanges
N/A
Address
349 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment include Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Executives
Kathy L Hibbs officer: See Remarks C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
William G Richards officer: Head of Therapeutics Discovery 160 KELLY AVE, HALF MOON BAY CA 94019
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Joseph Anthony Selsavage officer: Interim CFO 490 HILL STREET, APT 5, SAN FRANCISCO CA 94114
Kenneth J. Hillan officer: Head of Therapeutics C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Evan Lovell director, officer: Chief Financial Officer 27 SOUTH PARK STREET, SUITE 200, SAN FRANCISCO CA 94107
Hernandez Sandra R Md director BLACKBAUD INC, 2000 DANIEL ISLAND DRIVE, CHARLESTON SC 29492
Paul D Johnson officer: VP, General Manager-Consumer 440 N BARRANCA AVE #3550, COVINA CA 91723
Tracy Keim officer: See Remarks 6107 ARROWROOT LANE, RANCHO PALOS VERDES CA 90275
Steven Lemon officer: Vice President, Engineering 1020 CHERRY AVENUE, SAN JOSE CA 95125
Steven J Schoch officer: See Remarks 2748 BUSH STREET, SAN FRANCISCO CA 94115
Frederick Mark Kohler officer: Vice President, People 1004 UNION STREET, ALAMEDA CA 94501
Sequoia Capital Global Growth Ii Principals Fund, L.p. 10 percent owner 2800 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Abeec 2.0, Llc 10 percent owner 171 MAIN STREET, SUITE 259, LOS ALTOS CA 94022
Anne Wojcicki director, 10 percent owner, officer: Chief Executive Officer C/O AJAX I HOLDINGS, LLC, 667 MADISON AVENUE, NEW YORK NY 10606

23andMe Holding Co (23andMe Holding Co) Headlines